{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:42:51Z","timestamp":1774240971792,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.09.041","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:11:47Z","timestamp":1538572307000},"page":"324-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience"],"prefix":"10.1016","volume":"27","author":[{"given":"Emanuele","family":"D'Amico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Zangh\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Grazia","family":"Chisari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore Lo","family":"Fermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Zappia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2018.09.041_bib0001","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","article-title":"Efficacy and safety of Rituximab in relapsing and progressive multiple sclerosis: a hospital-based study","volume":"265","author":"Alcala","year":"2018","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2018.09.041_bib0002","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2018.09.041_bib0003","doi-asserted-by":"crossref","first-page":"E66308","DOI":"10.1371\/journal.pone.0066308","article-title":"Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review","volume":"8","author":"Castillo-Trivino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.09.041_bib0004","article-title":"Efficacy of Rituximab in refractory RRMS","author":"Durozard","year":"2018","journal-title":"Mult. Scler."},{"issue":"Suppl 3","key":"10.1016\/j.msard.2018.09.041_bib0005","first-page":"S3","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2018.09.041_bib0006","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of Rituximab treatment in patients with Neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2018.09.041_bib0007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of Neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2018.09.041_bib0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","article-title":"\"B-cells in MS and NMO: pathogenesis and therapy","volume":"36","author":"Krumbholz","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.msard.2018.09.041_bib0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinepi.2017.11.006","article-title":"Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials","volume":"94","author":"Ladanie","year":"2018","journal-title":"J. Clin. Epidemiol."},{"issue":"1-2","key":"10.1016\/j.msard.2018.09.041_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after Rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.msard.2018.09.041_bib0011","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with Neuromyelitis optica after repeated therapy with Rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2018.09.041_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","article-title":"\"Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.09.041_bib0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on Rituximab: a monoclonal antibody for B-cell non-Hodgkin lymphoma and other affections","volume":"97","author":"Seyfizadeh","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.msard.2018.09.041_bib0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"\"Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:16Z","timestamp":1761900316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"alternative-id":["S2211034818303596"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.041","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}